ADAMIS PHARMACEUTICALS CORP (ADMP)
US00547W3079 - Common Stock
| MRQ (2023-6-30) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | N/A | N/A | N/A | 6.86M | 8.81M | |||
| Cash Equivalents | 640.00K | 1.08M | 23.22M | 6.86M | 8.81M | |||
| Receivables | 20.00K | 1.09M | 5.90M | 1.09M | 1.88M | |||
| Inventories | 660.00K | 1.24M | 420.00K | 3.12M | 2.06M | |||
| Other Current Assets | 2.13M | 5.87M | 5.67M | 1.46M | 1.12M | |||
| Total Current Assets | 3.45M | 9.27M | 35.20M | 12.52M | 13.88M | |||
| Non-Current Assets | ||||||||
| PPE Net | 1.29M | 1.61M | 2.99M | 11.13M | 13.54M | |||
| Investments And Advances | N/A | N/A | N/A | N/A | N/A | |||
| Goodwill | N/A | N/A | N/A | 870.00K | 7.64M | |||
| Intangibles | N/A | N/A | N/A | 6.29M | 11.13M | |||
| Other Non-Current Assets | 10.00K | 50.00K | 110.00K | 50.00K | 1.65M | |||
| Total Non-Current Assets | 1.30M | 1.66M | 3.10M | 18.35M | 33.96M | |||
| TOTAL ASSETS | 4.75M | 10.93M | 38.30M | 30.87M | 47.84M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | 0.00 | 4.37M | 2.16M | |||
| Accrued Expenses | 2.53M | 2.16M | 5.69M | 11.96M | 2.87M | |||
| Accounts Payable | 11.37M | 7.94M | 3.75M | 3.49M | 4.27M | |||
| Other Current Liabilities | 1.11M | 1.30M | 1.78M | 100.00K | 120.00K | |||
| Total Current Liabilities | 15.01M | 11.40M | 11.22M | 19.93M | 9.41M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 890.00K | 0.00 | |||
| Deferred Taxes/Income | N/A | N/A | N/A | 110.00K | 110.00K | |||
| Other Non-Current Liabilities | 1.24M | 190.00K | 1.19M | 6.44M | 5.32M | |||
| Total Non-Current Liabilities | 1.23M | 180.00K | 1.20M | 7.44M | 5.43M | |||
| TOTAL LIABILITIES | 16.24M | 11.58M | 12.42M | 27.37M | 14.84M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -322.08M | -304.56M | -278.09M | -229.91M | -180.52M | |||
| Additional Paid In Capital | 310.25M | 303.75M | 303.96M | 233.40M | 213.52M | |||
| Common Shares | 350.00K | 180.00K | 20.00K | 10.00K | 10.00K | |||
| Treasury Stock | -10.00K | -10.00K | -10.00K | -10.00K | -10.00K | |||
| Shares Outstanding | 2.79M | 2.14M | 2.14M | 1.34M | 880.00K | |||
| Tangible Book Value per Share | -4.24 | -0.38 | 12.09 | -2.73 | 16.17 | |||
| Total Shareholders' Equity | -11.50M | -650.00K | 25.88M | 3.50M | 33.00M | |||
| TOTAL LIABILITIES AND EQUITY | 4.75M | 10.93M | 38.30M | 30.87M | 47.84M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | 0.25 | N/A | |||
| Current Ratio | 0.23 | 0.81 | 3.14 | 0.63 | 1.48 | |||
| Return On Assets (ROA) | -531.37% | -242.27% | -119.66% | -159.99% | -57.50% | |||
| Return On Equity (ROE) | N/A | N/A | -177.09% | -1411.14% | -83.36% | |||
All data in USD